<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39443527</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>24</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>26</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Atorvastatin and telmisartan do not reduce nasopharyngeal carriage of SARS-CoV-2 in mild or moderate COVID-19 in a phase IIb randomized controlled trial.</ArticleTitle><Pagination><StartPage>25028</StartPage><MedlinePgn>25028</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">25028</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-024-72449-1</ELocationID><Abstract><AbstractText>Observational studies suggest a reduction in fatal or severe COVID-19 disease with the use of ACE2 inhibitors and statins. We implemented a randomized controlled tree-arm open label trial evaluating the benefits of adding telmisartan (TLM) or atorvastatin (ATV) to lopinavir boosted ritonavir (LPVr) on the SARS-CoV-2 nasopharyngeal viral load in patients with mild / moderate COVID-19 infection in Côte d'Ivoire. RT-PCR positive COVID-19 patients ≥ 18 years, with general or respiratory symptoms for less than 7 days were randomized (1:1:1) to receive LPVr (400 mg/100 mg twice daily), LPVr + TLM (10 mg once daily) or LPVr + ATV (20 mg once daily) for 10 days. The primary endpoint was viro-inflammatory success defined as a composite variable at day 11: Ct ≥ 40 and C-reactive protein &lt; 27 mg/L. We randomized 294 patients: 96 to LPVr, 100 to LPVr + TLM, 98 to LPVr + ATV arms. Baseline characteristics were well balanced between arms. In the primary analysis (missing = failure), 46% patients in the LPVr arm reached viro-inflammatory success at day 11 vs 43% in the LPVr + TLM arm (p = 0.69) and 43% in the LPVr + ATV arm (p = 0.68). The median time from baseline to resolution of COVID-19 related symptoms was not different between arms. Nine patients were hospitalized: 2 in the LPVr arm, 5 in the LPVr + TLM arm and 2 in the LPVr + ATV arm and 4 patients died. Among adults with mild to moderate COVID-19 infection, the addition of telmisartan or atorvastatin, to the standard LPVr treatment is not associated with a better virological or clinical outcome.Trial registration: NCT04466241, registered on 10/07/2020.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bonnet</LastName><ForeName>Fabrice</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>National Institute for Health and Medical Research, (INSERM), UMR 1219, Research Institute for Sustainable Development (IRD), University of Bordeaux, Bordeaux Population Health Centre, EMR 271, Bordeaux, France. fabrice.bonnet@u-bordeaux.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Bordeaux, Service de Médecine Interne et Maladies Infectieuses, Hôpital Saint-André, 1 rue Jean Burguet, 33075, Bordeaux, France. fabrice.bonnet@u-bordeaux.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doumbia</LastName><ForeName>Adama</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unité Pédagogique de Dermatologie et Infectiologie, Unité de Formation et de Recherche des Sciences Médicales, Université Félix Houphouet-Boigny, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Treichville, University Hospital Medical Center at Treicheville, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Machault</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Institute for Health and Medical Research, (INSERM), UMR 1219, Research Institute for Sustainable Development (IRD), University of Bordeaux, Bordeaux Population Health Centre, EMR 271, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ello</LastName><ForeName>Frederic Nogbou</ForeName><Initials>FN</Initials><AffiliationInfo><Affiliation>Unité Pédagogique de Dermatologie et Infectiologie, Unité de Formation et de Recherche des Sciences Médicales, Université Félix Houphouet-Boigny, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Treichville, University Hospital Medical Center at Treicheville, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellecave</LastName><ForeName>Pantxika</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Laboratoire de Virologie, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akpovo</LastName><ForeName>Corine Bernice</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Unité Pédagogique de Dermatologie et Infectiologie, Unité de Formation et de Recherche des Sciences Médicales, Université Félix Houphouet-Boigny, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Treichville, University Hospital Medical Center at Treicheville, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sidibe</LastName><ForeName>Baba Toumany</ForeName><Initials>BT</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Treichville, University Hospital Medical Center at Treicheville, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>ANRS/Maladies Infectieuses Emergentes, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kouamé</LastName><ForeName>Antoine</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unité Pédagogique de Dermatologie et Infectiologie, Unité de Formation et de Recherche des Sciences Médicales, Université Félix Houphouet-Boigny, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adjogoua</LastName><ForeName>Edgard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dosso</LastName><ForeName>Mireille</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institut Pasteur de Côte d'Ivoire, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Niangoran</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Unité Pédagogique de Dermatologie et Infectiologie, Unité de Formation et de Recherche des Sciences Médicales, Université Félix Houphouet-Boigny, Abidjan, Côte d'Ivoire.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Journot</LastName><ForeName>Valérie</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>National Institute for Health and Medical Research, (INSERM), UMR 1219, Research Institute for Sustainable Development (IRD), University of Bordeaux, Bordeaux Population Health Centre, EMR 271, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eholié</LastName><ForeName>Serge Paul</ForeName><Initials>SP</Initials><AffiliationInfo><Affiliation>Unité Pédagogique de Dermatologie et Infectiologie, Unité de Formation et de Recherche des Sciences Médicales, Université Félix Houphouet-Boigny, Abidjan, Côte d'Ivoire. sergeholie@yahoo.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire de Treichville, University Hospital Medical Center at Treicheville, Abidjan, Côte d'Ivoire. sergeholie@yahoo.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Service des Maladies Infectieuses et Tropicales, Centre Hospitalier Universitaire de Treichville, Abidjan, Côte d'Ivoire. sergeholie@yahoo.fr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04466241</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>ECTZ 143960</GrantID><Agency>ANRS/MIE</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>A0JWA85V8F</RegistryNumber><NameOfSubstance UI="D000069059">Atorvastatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>U5SYW473RQ</RegistryNumber><NameOfSubstance UI="D000077333">Telmisartan</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069059" MajorTopicYN="Y">Atorvastatin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077333" MajorTopicYN="Y">Telmisartan</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009305" MajorTopicYN="Y">Nasopharynx</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019562" MajorTopicYN="Y">Viral Load</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Atorvastatin</Keyword><Keyword MajorTopicYN="N">Randomized controlled trial</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Telmisartan</Keyword></KeywordList><CoiStatement>Fabrice Bonnet has received consulting honoraria, research grants, or both from Gilead Sciences, MSD, and ViiV Healthcare, outside the submitted work. Other authors have nothing to disclose. The other authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>16</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39443527</ArticleId><ArticleId IdType="pmc">PMC11500379</ArticleId><ArticleId IdType="doi">10.1038/s41598-024-72449-1</ArticleId><ArticleId IdType="pii">10.1038/s41598-024-72449-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cao, B. et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N. Engl. J. Med.382, 1787–1799. 10.1056/NEJMoa2001282 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121492</ArticleId><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G, dos Santos Moreira Silva EA, Medeiros Silva DC, Thabane L, Singh G, Park JJH, et al. Effect of Early Treatment With Hydroxychloroquine or Lopinavir and Ritonavir on Risk of Hospitalization Among Patients With COVID-19 The TOGETHER Randomized Clinical Trial. JAMA Network Open, 10.1001/jamanetworkopen.2021.6468. (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8063069</ArticleId><ArticleId IdType="pubmed">33885775</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford, N. et al. Systematic review of the efficacy and safety of antiretroviral drugs against SARS, MERS or COVID-19: Initial assessment. JIAS10.1002/jia2.25489 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158851</ArticleId><ArticleId IdType="pubmed">32293807</ArticleId></ArticleIdList></Reference><Reference><Citation>Albini, A., Di Guardo, G., Noonan, D. M. &amp; Lombardo, M. The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based cardiovascular therapies. Intern Emerg. Med.15, 759–766. 10.1007/s11739-020-02364-6 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236433</ArticleId><ArticleId IdType="pubmed">32430651</ArticleId></ArticleIdList></Reference><Reference><Citation>Teixeira, L. et al. Simvastatin downregulates the SARS-CoV-2-induced inflammatory response and impairs viral infection through disruption of lipid rafts. Front. Immunol.10.3389/fimmu.2022.820131 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8895251</ArticleId><ArticleId IdType="pubmed">35251001</ArticleId></ArticleIdList></Reference><Reference><Citation>Fedson, D. S., Opal, S. M. &amp; Rordam, O. M. Hiding in plain sight: an approach to treating patients with severe COVID-19 infection. Mbio10.1128/mBio.00398-20 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7157814</ArticleId><ArticleId IdType="pubmed">32198163</ArticleId></ArticleIdList></Reference><Reference><Citation>Kow, C. S. &amp; Hasan, S. S. Meta-analysis of effect of statins in patients with COVID-19. Am. J. Cardiol.134, 153–155. 10.1016/j.amjcard.2020.08.004 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7419280</ArticleId><ArticleId IdType="pubmed">32891399</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen, L. et al. Statin use and in-hospital mortality in patients with COVID-19 and coronary heart disease. Sci. Rep.10.1038/s41598-021-02534-2 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8668894</ArticleId><ArticleId IdType="pubmed">34903765</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, W. et al. Statin use in hospitalized patients with COVID-19: A comprehensive analysis of the New York City public hospital system. Am. J. Med.135, 897–905. 10.1016/j.amjmed.2022.02.018 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8920066</ArticleId><ArticleId IdType="pubmed">35296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal, R., Banerjee, M., Yadav, U. &amp; Bhattacharjee, S. Statin use and clinical outcomes in patients with COVID-19: An updated systematic review and meta-analysis. Postgrad. Med. J.98, 354–359. 10.1136/postgradmedj-2020-139172 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33541927</ArticleId></ArticleIdList></Reference><Reference><Citation>de Mesquita, C. F. et al. Adjunctive statin therapy in patients with COVID-19: A systematic review analysis and meta-analysis of randomized controlled trials. Am. J. Med.10.1016/j.amjmed.2024.06.002.) (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38866303</ArticleId></ArticleIdList></Reference><Reference><Citation>Rong, Y. et al. Association of antecedent statin use on 30-day, 60-day and 90-day mortality among Mississippi Medicaid beneficiaries diagnosed with COVID-19. BMJ Open10.1136/bmjopen-2023-076195 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10660820</ArticleId><ArticleId IdType="pubmed">37984946</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuno, T., So, M., Iwagami, M., Takahashi, M. &amp; Egorova, N. N. The association of statins use with survival of patients with COVID-19. J. Cardiol.79, 494–500. 10.1016/j.jjcc.2021.12.012 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8692086</ArticleId><ArticleId IdType="pubmed">34974938</ArticleId></ArticleIdList></Reference><Reference><Citation>Wander, P. L. et al. Associations of statin use with 30-day adverse outcomes among 4 801 406 US Veterans with and without SARS-CoV-2: An observational cohort study. BMJ Open10.1136/bmjopen-2021-058363 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8889446</ArticleId><ArticleId IdType="pubmed">35304400</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt, C. M. et al. Medications associated with lower mortality in a SARS-CoV-2 positive cohort of 26,508 veterans. J. Gen. Intern. Med.37, 4144–4152. 10.1007/s11606-022-07701-3 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9243908</ArticleId><ArticleId IdType="pubmed">35768681</ArticleId></ArticleIdList></Reference><Reference><Citation>Rocheleau, G. L. Y. et al. Renin-angiotensin system pathway therapeutics associated with improved outcomes in males hospitalized with COVID-19. Crit. Care Med.50, 1306–1317. 10.1097/CCM.0000000000005589 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9380153</ArticleId><ArticleId IdType="pubmed">35607951</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin, J., Wang, C., Song, X., Li, X. &amp; Miao, M. Effects of renin-angiotensin system inhibitors on mortality and disease severity of COVID-19 patients: A meta-analysis of randomized controlled Trials. Am. J. Hypertens.35, 462–469. 10.1093/ajh/hpac001 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35512430</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery MM, Oliveira J E Silva L, Bellolio F, Garovic VD, Dempsey TM, et al. Association of outpatient use of renin-angiotensin-aldosterone system blockers on outcomes of acute respiratory illness during the COVID-19 pandemic: a cohort study. BMJ Open, 10.1136/bmjopen-2021-060305. (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9260198</ArticleId><ArticleId IdType="pubmed">35793915</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, Z. et al. Long-term oral ACEI/ARB therapy is associated with disease severity in elderly COVID-19 omicron BA.2 patients with hypertension. BMC Infect. Dis.10.1186/s12879-023-08913-6 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10726588</ArticleId><ArticleId IdType="pubmed">38110869</ArticleId></ArticleIdList></Reference><Reference><Citation>Little, S. J. Treatment of acute HIV infection and the potential role of acutely HIV-infected persons in cure studies. Top Antivir. Med.23, 156–160 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6148942</ArticleId><ArticleId IdType="pubmed">27398768</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulangu, S. et al. A randomized, controlled trial of ebola virus disease therapeutics. N. Engl. J. Med.10.1056/NEJMoa1910993 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10680050</ArticleId><ArticleId IdType="pubmed">31774950</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavnani, D. et al. SARS-CoV-2 viral load is associated with risk of transmission to household and community contacts. BMC Infect Dis.22, 672. 10.1186/s12879-022-07663-1 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9354300</ArticleId><ArticleId IdType="pubmed">35931971</ArticleId></ArticleIdList></Reference><Reference><Citation>Havlir, D. V. et al. HIV testing and treatment with the use of a community health approach in rural Africa. N. Engl. J. Med.381, 219–229. 10.1056/NEJMoa1809866 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6748325</ArticleId><ArticleId IdType="pubmed">31314966</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng, S. et al. Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China, January-March 2020: retrospective cohort study. BMJ10.1136/bmj.m1443 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7190077</ArticleId><ArticleId IdType="pubmed">32317267</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, G. et al. C-Reactive protein level may predict the risk of COVID-19 aggravation. Open Forum Infect Dis10.1093/ofid/ofaa153 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7197542</ArticleId><ArticleId IdType="pubmed">32455147</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghati, N. et al. Statin and aspirin as adjuvant therapy in hospitalised patients with SARS-CoV-2 infection: A randomised clinical trial (RESIST trial). BMC Infect Dis.202, 606. 10.1186/s12879-022-07570-5 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9270743</ArticleId><ArticleId IdType="pubmed">35810307</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaitan-Duarte, H. G. et al. Effectiveness of rosuvastatin plus colchicine, emtricitabine/tenofovir and combinations thereof in hospitalized patients with COVID-19: A pragmatic, open-label randomized trial. E Clin. Med.10.1016/j.eclinm.2021.101242 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8686571</ArticleId><ArticleId IdType="pubmed">34957385</ArticleId></ArticleIdList></Reference><Reference><Citation>INSPIRATION-S Investigators. Atorvastatin versus placebo in patients with covid-19 in intensive care: randomized controlled trial. BMJ10.1136/bmj-2021-068407 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34996756</ArticleId></ArticleIdList></Reference><Reference><Citation>The REMAP-CAP Investigators. Simvastatin in critically Ill patients with Covid-19. N. Engl. J. Med.389(25), 2341–2354. 10.1056/NEJMoa2309995 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10755839</ArticleId><ArticleId IdType="pubmed">37888913</ArticleId></ArticleIdList></Reference><Reference><Citation>Makris, D. et al. Effect of pravastatin on the frequency of ventilator-associated pneumonia and on intensive care unit mortality: Open-label, randomized study. Crit. Care Med.39, 2440–2446 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21725239</ArticleId></ArticleIdList></Reference><Reference><Citation>Papazian, L. et al. Effect of statin therapy on mortality in patients with ventilator-associated pneumonia: A randomized clinical trial. JAMA10.1001/jama.2013.280031 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24108510</ArticleId></ArticleIdList></Reference><Reference><Citation>Franco, R. et al. SARS-CoV-2 as a factor to disbalance the reninangiotensin system: a suspect in the case of exacerbated IL-6 production. J. Immunol.205, 1198. 10.4049/jimmunol.2000642 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32680957</ArticleId></ArticleIdList></Reference><Reference><Citation>Duarte, M. et al. Telmisartan for treatment of Covid-19 patients: An open multicenter randomized clinical trial. E Clin. Med.10.1016/j.eclinm.2021.100962 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8225700</ArticleId><ArticleId IdType="pubmed">34189447</ArticleId></ArticleIdList></Reference><Reference><Citation>Jardine, M. J. et al. Angiotensin receptor blockers for the treatment of covid-19: Pragmatic, adaptive, multicentre, phase 3, randomised controlled trial. BMJ10.1136/bmj-2022-072175 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9667467</ArticleId><ArticleId IdType="pubmed">36384746</ArticleId></ArticleIdList></Reference><Reference><Citation>Anoh, E. A. et al. Subregional origins of emerging SARS-CoV-2 variants during the second pandemic wave in Côte d’Ivoire. Virus Genes59, 370–376. 10.1007/s11262-023-01984-2 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10023306</ArticleId><ArticleId IdType="pubmed">36932280</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>